DEFA14A: Unicycive Therapeutics Amends Proxy Statement to Clarify Voting Rights and Quorum Requirements for Annual Meeting

Unicycive Therapeutics amends its proxy statement to clarify the voting rights of Series A and B Preferred Stock and the quorum requirements for its upcoming annual meeting on June 9, 2025.

Summary

• Unicycive Therapeutics has amended its proxy statement for the annual meeting of stockholders to be held on June 9, 2025.
• The amendment clarifies the number of votes available to holders of Series A and Series B Preferred Stock.
• It also clarifies the total number of shares that must be present in person or by proxy to constitute a quorum for the Annual Meeting.
• As of the record date of April 30, 2025, there were 120,629,281 shares of common stock outstanding.
• There were also 5,464.21 shares of Series A Preferred Stock and 3,000 shares of Series B Preferred Stock outstanding.
• Only 1,816.33102 shares of Series A Preferred Stock are eligible to vote, convertible into 5,068,068 shares of common stock.
• Only 1,189.718 shares of Series B Preferred Stock are eligible to vote, convertible into 1,189,718 shares of common stock.
• The aggregate amount of shares eligible to vote at the meeting is 126,887,067.
• A quorum requires 63,443,535 shares to be represented in person or by proxy.

Sentiment

Score: 7

Explanation: The document is a neutral, factual amendment to a proxy statement, clarifying voting procedures. It doesn't contain any particularly positive or negative information, but ensures transparency for shareholders.

Future Outlook

The document outlines the voting process and quorum requirements for the upcoming annual meeting, ensuring stockholders are informed about their rights and the procedures for participation.

Industry Context

This announcement is a standard regulatory filing related to corporate governance and shareholder meetings. It ensures transparency and compliance with SEC regulations.

Stakeholder Impact

• Shareholders are directly impacted by the clarification of voting rights and quorum requirements.
• The amendment ensures that all shareholders are aware of their voting power and how to participate in the Annual Meeting.

Next Steps

• Stockholders should review the amended proxy statement in conjunction with the original proxy statement.
• Stockholders should submit their votes as instructed in the proxy statement.
• Attend or submit a proxy for the Annual Meeting on June 9, 2025.

Key Dates

Keywords

Proxy Statement, Annual Meeting, Voting Rights, Series A Preferred Stock, Series B Preferred Stock, Quorum, Unicycive Therapeutics, Amendment